The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: Risks, benefits, and management

Medicine & Life Sciences

• microsomal triglyceride transfer protein 100%
• Hyperlipoproteinemia Type II 79%
• Risk Management 69%
• Risk Assessment 53%
• Blood Component Removal 39%
• oxidized low density lipoprotein 32%
• LDL Cholesterol 28%
• Proteins 23%
• Chylomicrons 21%
• Lipids 20%
• VLDL Lipoproteins 19%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 15%
• Triglycerides 12%
• Cholesterol 11%
• Therapeutics 10%
• Costs and Cost Analysis 9%
• Liver 8%
• Pharmaceutical Preparations 6%